+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes--a phase-I/II trial



Recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes--a phase-I/II trial



Onkologie 11(1): 53-55



A phase-I/II trial was initiated to study the effect of rhGM-CSF in patients with myelodysplastic syndromes who were not eligible for other kinds of therapy, rhGM-CSF was given to 9 patients in doses of 15 micrograms/m2-150 micrograms/m2 as an intravenous 8-h infusion for a cycle of 7 days followed by an interval of 14 days and a second 7-day treatment course. A dose-dependent increase in the leukocyte count was observed in 7 out of 9 patients. No change in reticulocyte numbers was seen and only 1 patient experienced an increase in platelet count. Toxicity mainly consisted of mild local phlebitis at the site of infusion and sternal pain after bolus injection.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 041189068

Download citation: RISBibTeXText

PMID: 3283627


Related references

Recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes--a phase I/II trial. Blood 73(1): 31-37, 1989

Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor in Patients with Myelodysplastic Syndromes a Phase-I/Ii Trial. Oncology Research and Treatment 11(1): 53-55, 1988

Recombinant human granulocyte-macrophage colony-stimulating factor and low-dose cytosine-arabinoside in the treatment of patients with myelodysplastic syndromes. A phase II study. Onkologie 13(1): 33-37, 1990

A phase II trial of recombinant human granulocyte colony-stimulating factor in the myelodysplastic syndromes. British Journal of Haematology 78(3): 378-384, 1991

Recombinant human erythropoietin in combined treatment with granulocyte- or granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes. Journal of Cancer Research and Clinical Oncology 128(9): 497-502, 2002

A randomized phase-I/II multicenter study of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) therapy for patients with myelodysplastic syndromes and a relatively low risk of acute leukemia. Annals of Hematology 64(6): 312-312, 1992

Treatment of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor. A phase I-II trial. Annals of Internal Medicine 110(12): 976-984, 1989

Effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes. New England Journal of Medicine 317(25): 1545-1552, 1987

Effects of low doses of recombinant human granulocyte-macrophage colony stimulating factor (GM-CSF) in patients with myelodysplastic syndromes. British Journal of Haematology 77(3): 291-295, 1991

Treatment with recombinant human granulocyte macrophage colony stimulating factor rhgm csf in patients with myelodysplastic syndromes mds. Experimental Hematology 16(6): 520, 1988

Recombinant human granulocyte-macrophage colony-stimulating factor plus recombinant human erythropoietin may improve anemia in selected patients with myelodysplastic syndromes. American Journal of Hematology 44(4): 229-236, 1993

Response to recombinant human erythropoietin and granulocyte macrophage colony-stimulating factor in patients with low-risk myelodysplastic syndromes. Blood 90(10 Suppl. 1 Part 1): 84A, 1997

Recombinant human granulocyte-macrophage colony-stimulating factor plus erythropoietin for the treatment of cytopenias in patients with myelodysplastic syndromes. British Journal of Haematology 105(1): 141-148, 1999

Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor and Low-Dose Cytosine-Arabinoside in the Treatment of Patients with Myelodysplastic Syndromes. Oncology Research and Treatment 13(1): 33-37, 1990

Growth of human hematopoietic colonies from patients with myelodysplastic syndromes in response to recombinant human granulocyte-macrophage colony-stimulating factor. Leukemia 3(5): 363-366, 1989